|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...138139140141142143144145146147148...156157» |
- | Benlysta (belimumab) / GSK
Trial completion, IO biomarker: BELISS: Efficacy and Safety of Belimumab in Subjects With Primary Sj (clinicaltrials.gov) - Jun 30, 2012
P2, N=20, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed
- ||||||| hydroxychloroquine / Generic mfg.
Trial completion: JOQUER: Hydroxychloroquine Versus Placebo in Primary Sj (clinicaltrials.gov) - Jun 30, 2012
P3, N=120, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS (clinicaltrials.gov) - Jun 28, 2012
P=N/A, N=50, Recruiting, Sponsor: University of Southern California
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| dalfampridine / Generic mfg.
Enrollment open: Fampridine Pregnancy Exposure Registry (clinicaltrials.gov) - Jun 27, 2012
P=N/A, N=375, Recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Orencia (abatacept) / BMS
Enrollment change, Combination therapy: ACCESS: Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (clinicaltrials.gov) - Jun 26, 2012
P2, N=137, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=100 --> 137
- Orencia (abatacept) / BMS
Enrollment closed, Combination therapy: ACCESS: Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (clinicaltrials.gov) - Jun 26, 2012
P2, N=137, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 137 Recruiting --> Active, not recruiting
- leucovorin calcium / Generic mfg.
Enrollment open: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Jun 26, 2012
P2, N=144, Recruiting, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change: Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=36, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Recruiting N=60 --> 36
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=36, Completed, Sponsor: University of California, Los Angeles
N=60 --> 36 Recruiting --> Completed
- omega-3 ethylester concentrate / Generic mfg.
Trial completion: Efficacy of Fish Oil in Lupus Patients (clinicaltrials.gov) - Jun 25, 2012
P4, N=106, Completed, Sponsor: Michelle Petri M.D.,MPH
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion, P3 data: Phase IIIB Subcutaneous Missed Dose Study (clinicaltrials.gov) - Jun 25, 2012
P3, N=270, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial, Compliance: Closing the Loop in Adolescents During Non-compliance Behaviours (clinicaltrials.gov) - Jun 25, 2012
P2, N=12, Completed, Sponsor: University of Cambridge
- New P2 trial: Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes: Evaluation of Reduced Meal Bolusing (clinicaltrials.gov) - Jun 25, 2012
P2, N=8, Completed, Sponsor: University of Cambridge
- |||| tabalumab (LY2127399) / Eli Lilly
Trial completion: A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 21, 2012
P2, N=245, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: Closing the Loop in Youth With Type 1 Diabetes in the Home Setting (clinicaltrials.gov) - Jun 21, 2012
P2, N=17, Completed, Sponsor: University of Cambridge
Active, not recruiting --> Completed Initiation date: Jan 2011 --> Jun 2012
- Rituxan (rituximab) / Roche
Trial completion: Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab (clinicaltrials.gov) - Jun 21, 2012
P3, N=22, Completed, Sponsor: University Hospital, Rouen
Initiation date: Jan 2011 --> Jun 2012 Recruiting --> Completed
- Trial completion: APCam05: Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes (clinicaltrials.gov) - Jun 21, 2012
P=N/A, N=16, Completed, Sponsor: University of Cambridge
Recruiting --> Completed Recruiting --> Completed
- ||||| itacitinib (INCB039110) / Incyte
New P2 trial: A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 20, 2012
P2, N=106, Completed, Sponsor: Incyte Corporation
- || New P3 trial: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Jun 19, 2012
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Enrollment closed: Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes (clinicaltrials.gov) - Jun 18, 2012
P3, N=458, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Completed Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg.
Enrollment change, Adverse events: Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=222, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting N=100 --> 222
- cyclophosphamide / Generic mfg.
Trial completion, Adverse events: Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=222, Completed, Sponsor: Sun Yat-sen University
N=100 --> 222 Recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial initiation date: Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis (clinicaltrials.gov) - Jun 17, 2012
P3, N=19, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Initiation date: Oct 2011 --> Feb 2012
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
Enrollment open: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jun 17, 2012
P1, N=28, Recruiting, Sponsor: MedImmune LLC
Initiation date: Oct 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- New P4 trial: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Jun 14, 2012
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- |||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Trial completion: A Study in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 14, 2012
P2, N=429, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | PF-5230895 / Emergent Biosolutions, Pfizer
Trial completion: Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 14, 2012
P1, N=20, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- zoledronic acid / Generic mfg.
Enrollment change: EXALT: Zoledronic Acid in MS-patients With Osteoporosis (clinicaltrials.gov) - Jun 13, 2012
P3, N=29, Terminated, Sponsor: Novartis
Active, not recruiting --> Completed N=200 --> 29
- | Rebif (human IFN-β-1a) / EMD Serono
Trial completion: The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment (clinicaltrials.gov) - Jun 13, 2012
P=N/A, N=20, Completed, Sponsor: University of South Florida
N=200 --> 29 Enrolling by invitation --> Completed
- Nucala (mepolizumab) / GSK
Trial completion: MEPOCHUSS: Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome (clinicaltrials.gov) - Jun 13, 2012
P2, N=10, Completed, Sponsor: University of Schleswig-Holstein
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Enrollment change: A Randomized Exercise Trial for Wheelchair Users (clinicaltrials.gov) - Jun 12, 2012
P=N/A, N=135, Completed, Sponsor: University of Kansas
Active, not recruiting --> Completed N=180 --> 135
- Trial completion: A Randomized Exercise Trial for Wheelchair Users (clinicaltrials.gov) - Jun 12, 2012
P=N/A, N=135, Completed, Sponsor: University of Kansas
N=180 --> 135 Active, not recruiting --> Completed
- Trial withdrawal, IO biomarker: WIRMS-1: Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. (clinicaltrials.gov) - Jun 12, 2012
P2, N=0, Withdrawn, Sponsor: University of Nottingham
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change, IO biomarker: WIRMS-1: Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. (clinicaltrials.gov) - Jun 12, 2012
P2, N=0, Withdrawn, Sponsor: University of Nottingham
Not yet recruiting --> Withdrawn N=30 --> 0
- | Otrexup (methotrexate) / Antares
New P2 trial: Comparison of Methotrexate (MTX) and the VIBEX (clinicaltrials.gov) - Jun 12, 2012
P2, N=49, Completed, Sponsor: Antares Pharma Inc.
- ||||| Otrexup (methotrexate) / Antares
New P2 trial: Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX (clinicaltrials.gov) - Jun 12, 2012
P2, N=101, Completed, Sponsor: Antares Pharma Inc.
- | DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 12, 2012
P1, N=22, Completed, Sponsor: Novo Nordisk
N=30 --> 0 Active, not recruiting --> Completed
- Clinical: N-3 PUFA and Rheumatoid Arthritis in Korea (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=109, Completed, Sponsor: Hanyang University
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
Clinical: Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety. (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=50, Completed, Sponsor: Henri Mondor University Hospital
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 11, 2012
P1, N=52, Completed, Sponsor: Novo Nordisk
- Clinical: Orofacial Evaluation in Women With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=150, Completed, Sponsor: Federal University of São Paulo
- Enrollment open: An Internet-based Self-management Program for Adolescents With Arthritis (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=294, Recruiting, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical: An Observational Study of RoActemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Non-Biological DMARDs (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
- ||| Trial completion: Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=293, Completed, Sponsor: Becton, Dickinson and Company
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- memantine / Generic mfg.
Trial termination: Memantine-MS: Memantine Therapy for Multiple Sclerosis (clinicaltrials.gov) - Jun 6, 2012
P2, N=20, Terminated, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Active, not recruiting --> Completed Suspended --> Terminated; Unexpected side-effects: reversible and mild to moderate neurological impairment
- | Epratucyn (epratuzumab) / Gilead
Enrollment change: Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jun 5, 2012
P3, N=54, Terminated, Sponsor: UCB, Inc.
Suspended --> Terminated; Unexpected side-effects: reversible and mild to moderate neurological impairment N=300 --> 54
- |||| Enrollment open: Effect of CSII and CGM on Progression of Late Diabetic Complications (clinicaltrials.gov) - Jun 5, 2012
P4, N=80, Recruiting, Sponsor: Steen Andersen
N=300 --> 54 Not yet recruiting --> Recruiting
- || Enrollment change, Adherence: Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=1149, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=4320 --> 1149
- ||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (clinicaltrials.gov) - Jun 4, 2012
P3, N=127, Completed, Sponsor: Pfizer
N=4320 --> 1149 N=100 --> 127
- || New P2/3 trial: TRIFRA: Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 4, 2012
P2/3, N=201, Completed, Sponsor: Peking Union Medical College Hospital